Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 11/20 | 0.62 |
| ▸ | SRD5A2 | P31213 | 10/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.62 |
| ▸ | HSD3B1 | P14060 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | THPO | P40225 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13403374 | 1.00 | SRD5A1 (0.62) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL8726851 | 0.90 | SRD5A1 (0.60) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL8726862 | 0.90 | SRD5A1 (0.60) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL14336564 | 0.89 | SRD5A1 (0.61) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL25771570 | 0.88 | SRD5A1 (0.62) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL8156525 | 0.88 | SRD5A1 (0.62) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL8156524 | 0.88 | SRD5A1 (0.62) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL25772413 | 0.88 | SRD5A1 (0.62) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL8679765 | 0.87 | SRD5A1 (0.62) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL8679763 | 0.87 | SRD5A1 (0.62) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7696217-B2 | 17-acetamido-4-azasteroid derivatives as androgen receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2010-04-13 | — | — | US | disclosed |
| EP-1641535-A4 | 17-ACETAMIDO-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2008-05-14 | — | — | EP | disclosed |
| US-7312229-B2 | 21-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators | MERCK & CO., INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20070088047-A1 | 21-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2007-04-19 | — | — | US | disclosed |
| EP-1696925-A2 | 21-HETEROCYCLIC-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2006-09-06 | — | — | EP | disclosed |
| EP-1641535-A2 | 17-ACETAMIDO-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2006-04-05 | — | — | EP | disclosed |
| US-RE39056-E1 | 4-Azasteroids for treatment of hyperandrogenic conditions | MERCK & CO, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| WO-2005044988-A2 | 21-HETEROCYCLIC-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2005-05-19 | — | — | WO | disclosed |
| WO-2005005380-A2 | 17-ACETAMIDO-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2005-01-20 | — | — | WO | disclosed |
| US-6001844-A | 4-Azasteroids for treatment of hyperandrogenic conditions | MERCK & CO., INC. (US) | 1999-12-14 | — | — | US | disclosed |
| EP-0641209-A4 | NEW 17-ESTER, AMIDE, AND KETONE DERIVATIVES OF 3-OXO-4-AZASTEROIDS AS 5A-REDUCTASE INHIBITORS. | MERCK & CO INC (US) | 1995-08-23 | — | — | EP | disclosed |
| EP-0641209-A1 | NEW 17-ESTER, AMIDE, AND KETONE DERIVATIVES OF 3-OXO-4-AZASTEROIDS AS 5A-REDUCTASE INHIBITORS | MERCK & CO. INC. (US) | 1995-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088047-A1 | 21-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators | NR5A1, AR, NR3C1 | SRD5A1 11/4885SRD5A2 17/4885LMNA 3238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.